Prot #8951-CL-0301: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative,

Project: Research project

Project Details

StatusFinished
Effective start/end date1/27/20 → 1/27/23

Funding

  • Parexel (Prot #8951-CL-0301)
  • Astellas Pharma Global Development, Inc. (Prot #8951-CL-0301)